Vanda Pharmaceuticals (VNDA)

• Market cap: $250M
• 1 day: -1.39%
• 5 days: -1.16%
• 1 month: -11.64%
• 3 months: -4.49%
• 6 months: -6.59%
• Year to date: -11.83%
• 1 year: -5.13%
• 5 years: -64.64%
• 10 years: -55.26%
• Sector: Healthcare
• Industry: Biotechnology

About: Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Employees: 368

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

23% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 43

23% more call options, than puts

Call options by funds: $261K | Put options by funds: $212K

0% more capital invested

Capital invested by funds: $206M [Q3] → $206M (+$745K) [Q4]

1.33% less ownership

Funds ownership: 75.26% [Q3] → 73.93% (-1.33%) [Q4]

4% less funds holding

Funds holding: 151 [Q3] → 145 (-6) [Q4]

12% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 25

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $20 371% upside
• Avg. target: $20 371% upside
• High target: $20 371% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 36% 1-year accuracy 117 / 329 met price target

371% upside $20

Buy Reiterated

1 Apr 2025